Sugi Predict

Sugi Predict / Compounds / SCHEMBL20135113

SCHEMBL20135113

SCHEMBL20135113

Cc1ccc(N2CCN(C(=O)c3ccc([C@@]4(C(C)C)NC(=O)NC4=O)cc3)CC2)cc1C

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.49
▸ ALDH1A1 P00352 3/20 0.47
▸ TSHR P16473 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ MAPT P10636 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ ADAMTS5 Q9UNA0 8/20 0.42
▸ ADAM17 P78536 4/20 0.41
▸ MMP13 P45452 2/20 0.41
▸ MMP2 P08253 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135116 1.00 HTT (0.49) HTTALDH1A1TSHRSMN1; SMN2NPSR1
SCHEMBL20134996 0.86 ADAMTS5 (0.55) HTTALDH1A1TSHRNPSR1MAPT
SCHEMBL20134998 0.86 ADAMTS5 (0.55) HTTALDH1A1TSHRNPSR1MAPT
SCHEMBL29688606 0.86 ADAMTS5 (0.55) HTTALDH1A1TSHRNPSR1MAPT
SCHEMBL20135672 0.84 SMN1; SMN2 (0.47) HTTALDH1A1TSHRSMN1; SMN2NPSR1
SCHEMBL20135673 0.84 SMN1; SMN2 (0.47) HTTALDH1A1TSHRSMN1; SMN2NPSR1
SCHEMBL20134817 0.82 ALDH1A1 (0.37) HTTALDH1A1TSHRSMN1; SMN2NPSR1
SCHEMBL29688621 0.82 ALDH1A1 (0.37) HTTALDH1A1TSHRSMN1; SMN2NPSR1
SCHEMBL20135533 0.81 LMNA (0.55) HTTALDH1A1TSHRSMN1; SMN2NPSR1
SCHEMBL29688768 0.81 LMNA (0.55) HTTALDH1A1TSHRSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 — — CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 HTT 3274/4885ALDH1A1 584/4885TSHR 3522/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 HTT 3414/4885ALDH1A1 610/4885TSHR 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.